New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan ...

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers (the "Code"), the Company confirms that, as at close of business on 18 February 2026, its issued share capital consisted of ...

Oxford-based cell and gene therapy firm OXB has reported significant growth in its latest preliminary results – a trend it expects to continue throughout the current financial year. The business ...

Detailed price information for Oxford Biomedica Plc New (OXBDF) from The Globe and Mail including charting and trades.

Earnings call Oxford Biomedica reported FY2025 revenue of GBP 170.9m, up 33% YoY, and achieved its first full-year EBITDA profit (GBP 8.1m). The company ended the year with GBP 96.9m cash and a 36% ...

Oxford, UK - 01 April 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that in accordance with the FCA's Disclosure Guidance and ...

On September 28, 2025, in Hadayek October, Egypt, a security video captured a light road accident involving a Kia Sportage.

Mark Hartley breaks down the financial advantages a Stocks and Shares ISA can offer through its generous tax benefits. But ...

This latest recognition follows OXB’s previous success at the CDMO Leadership Awards in 2025, when the Company was named a winner in the ‘Cell & Gene Therapy – Global’ category, and later recognised ...

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ ...